University of California/Tufts CTSI
Aug 8, 2025, 17:15
Patent Foramen Ovale and Stroke: David Kent and Andy Wang Break It Down
Vasculearn Network shared an insightful post on LinkedIn:
”ICYMI: PFO and Stroke – Who Benefits from Closure?
About 1 in 4 adults has a PFO, but not everyone needs it closed. A new July 2025 JAMA review reframes PFO closure as targeted, not routine, therapy for select stroke patients.
Key tools guiding treatment:
- RoPE score: Predicts if stroke is PFO-related
- PASCAL system: Adds anatomy to assess stroke causality
Best candidates?
- Age ≤60
- Cryptogenic stroke
- High PASCAL score
- No vascular risk factors
In these patients, closure cuts stroke recurrence risk by up to 90% at 2 years.
Everyone else? Medical therapy still leads with individualized decisions on antiplatelet vs. anticoagulant”
Find the full update on the community.
Read the full article here.
Article: Patent Foramen Ovale and Stroke. A Review
Authors: David M. Kent, Andy Y. Wang
Stay informed on all the scientific advances in hematology with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications